Nexavar in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies
24-Jul-2009 -
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination ...
Bayer
Bayer HealthCare
breast cancer
+7